Co-Diagnostics outlines FDA dual 510(k) and CLIA waiver submission as cash falls to $3.6 M

Co-Diagnostics is progressing with FDA dual 510(k) and CLIA waiver submissions for its diagnostic products while its cash reserves have fallen to $3.6 million, highlighting critical regulatory milestones amid financial tightening.

This Wire brief sits within Fusion42's coverage of Diagnostics.